Home / Market News / $ACAD
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

Oppenheimer Adjusts Acadia Pharmaceuticals Price Target to $21

Nov 18, 2026, 2:38 PM UTC · Primary ticker $ACAD

Oppenheimer has lowered its price target for Acadia Pharmaceuticals (ACAD) from $23 to $21, while keeping a 'Perform' rating. This adjustment signals a slightly less optimistic view on the company's future pipeline prospects, which could lead to minor negative sentiment for the stock.

Oppenheimer, a prominent analyst firm, adjusted its price target for Acadia Pharmaceuticals (ACAD) down to $21 from $23. This change, while maintaining a 'Perform' rating, indicates a revised, slightly less favorable outlook on the company's drug pipeline. For traders, this is a moderately negative signal in the short term, as it reflects a professional assessment of reduced future potential. The primary impact is on ACAD shareholders, who might see some downward pressure or dampened enthusiasm. Long-term implications depend on whether Acadia's pipeline developments can outperform this revised analyst expectation, presenting a potential opportunity if the market overreacts to this minor downgrade.

$ACAD negative Price target lowered by Oppenheimer
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.